Using surrogate failure time data to increase cost effectiveness in clinical trials
利用替代失效时间数据提高临床试验的成本效益AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确关注主要终点的治疗效应检验,并将随访安排的随机化作为方法要求。
利用替代失效时间数据提高临床试验的成本效益AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
In clinical trials with failure time, outcomes, the cost of follow-up for the endpoint of primary interest is sometimes expensive. In many of these settings, one or more secondary or surrogate failure time outcomes are also available which either occur much earlier or are much less expensive to follow than the primary outcome. This paper presents a method for using these secondary outcomes to increase the power of detecting a treatment effect on the primary outcome only, without introducing bias. The proposed method requires that patients be randomized to either extended or limited follow-up. A test statistic is constructed by forming a minimum variance linear combination of a linear rank statistic based on the primary outcome and a mean zero weighted sum of linear rank statistics based on secondary outcomes from both follow-up arms. Large-sample distribution theory for this statistic is developed while moderate sample behaviour is explored through a simulation study.